EWTX

Edgewise TherapeuticsB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-03

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

30%

Probability

Target price

$50.00

+38.1% vs current

Most likely

Base case

45%

Probability

Target price

$40.00

+10.5% vs current

B-

Bear case

25%

Probability

Target price

$24.00

-33.7% vs current

AI sentiment snapshot

Latest data as of 2026-05-09

AI commentary

As of May 9, 2026, sentiment is cautiously constructive but not emphatic. Primary company materials were positive on long-term sevasemten data and reaffirmed Q2/Q4 milestones, yet the market reaction is muted: EWTX was $35.32 at the latest checked trade versus the May 7, 2026 anchor close of $35.58, about 0.7% lower. No trustworthy post-print analyst revision wave or clear consensus beat/miss dataset was confirmed in checked sources, so this still reads as a monitoring-style setup rather than a fully validated post-earnings rerating.

RankAlpha Sentiment Codex - 2026-05-09

Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-06-30eventCIRRUS-HCM 12-week Part D data due in Q2 2026High impact

Management said 12-week CIRRUS-HCM data for EDG-7500 in obstructive and nonobstructive HCM are expected in Q2 2026, making this the nearest high-impact readout from the May 7, 2026 earnings update [#8-K-2026-05-07].

2026-09-30catalystHFpEF expansion could broaden the EDG-15400 story in 2H 2026High impact

Edgewise said it expects to initiate a Phase 2 HFpEF trial for EDG-15400 in the second half of 2026, which could expand the cardiovascular narrative beyond HCM if execution stays on track [#8-K-2026-05-07].

2026-12-31catalystGRAND CANYON pivotal Becker readout remains the core value driverHigh impact

The company reiterated that pivotal GRAND CANYON top-line results for sevasemten in Becker muscular dystrophy are expected in Q4 2026; this remains the main thesis-changing catalyst and potential path toward a first marketing application [#8-K-2026-05-07].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-09 • Updated nightlySource: Internal modelMethodology